Oxford BioMedica Revenue Jumps 33%, Targets 2026 Growth

Key Financial Highlights

Oxford BioMedica announced preliminary 2025 revenue of £168.70 million, marking a 33% increase that surpassed the consensus analyst estimate of £166.22 million.

The company achieved a positive operating EBITDA of £2.30 million, a significant turnaround attributed to strong revenue growth and effective cost control measures, despite reporting an operating loss of £22.50 million for the full year.

Detailed Performance and Expansion

The revenue surge was primarily driven by increased lentiviral vector GMP manufacturing for clinical and commercial launch programs. Higher development revenues from clients advancing through clinical stages also contributed significantly.

Furthermore, the company experienced growth in procurement and storage services as clients prepared for commercialization. A key strategic move was the acquisition of an FDA-approved viral vector facility in Durham, North Carolina, enhancing its US manufacturing footprint.

Future Outlook and Projections

For 2026, Oxford BioMedica projects revenue between £220 million and £240 million, with an operating EBITDA margin of approximately 10%. The company noted that both revenue and EBITDA for 2026 will be weighted towards the second half of the year due to technology transfers and the new facility's ramp-up.

Looking ahead, the company forecasts robust medium-term revenue growth of 25% to 30% for 2027-28 and targets an EBITDA margin of at least 20% by 2027, signaling strong confidence in its long-term strategy.

Summary

Oxford BioMedica has demonstrated strong financial performance in 2025 and laid out an ambitious roadmap for future expansion. The company's strategic investments and positive forecasts position it for significant growth within the competitive cell and gene therapy manufacturing sector.

FAQ

Q: What was Oxford BioMedica's reported revenue for 2025?
A: The company reported preliminary revenue of £168.70 million, a 33% year-over-year increase.

Q: What is the company's financial outlook for 2026?
A: Oxford BioMedica expects 2026 revenue to be between £220 million and £240 million with an operating EBITDA margin of around 10%.

Q: What major acquisition did Oxford BioMedica make?
A: The company acquired an FDA-approved viral vector manufacturing facility in Durham, North Carolina, to expand its US capabilities.

Source: Investing.com